BioCentury
ARTICLE | Company News

Ciclofilin, ContraVir Pharmaceuticals deal

June 27, 2016 7:00 AM UTC

ContraVir acquired fellow HBV company Ciclofilin for up to $17 million in development and regulatory milestones related to Ciclofilin’s CPI-431-32. ContraVir said CPI-431-32 might “someday” be used i...